EP 1448210 A2 20040825 - REGULATION OF cGMP-SPECIFIC PHOSPHODIESTERASE 9A
Title (en)
REGULATION OF cGMP-SPECIFIC PHOSPHODIESTERASE 9A
Title (de)
REGULATION DER cGMP-SPEZIFISCHEN PHOSPHODIESTERASE 9A
Title (fr)
REGULATION DE LA PHOSPHODIESTERASE 9A SPECIFIQUE DU GMPc
Publication
Application
Priority
- DE 10156249 A 20011115
- EP 0212550 W 20021111
Abstract (en)
[origin: WO03041725A2] The invention relates to the use of PDE9A inhibitors for producing a pharmaceutical for the treatment and/or prophylaxis of coronary heart diseases, especially stable and unstable angina pectoris, acute myocardial infarction, the prophylaxis of myocardial infarction, sudden cardiac death, heart failure, and hypertension, peripheral circulatory disturbances and arteriosclerosis.
IPC 1-7
IPC 8 full level
C12Q 1/68 (2006.01); A61K 38/46 (2006.01); A61K 45/00 (2006.01); A61P 9/00 (2006.01); A61P 9/04 (2006.01); A61P 9/08 (2006.01); A61P 9/10 (2006.01); A61P 9/12 (2006.01); A61P 43/00 (2006.01)
CPC (source: EP US)
A61K 38/465 (2013.01 - EP US); A61P 9/00 (2017.12 - EP); A61P 9/04 (2017.12 - EP); A61P 9/08 (2017.12 - EP); A61P 9/10 (2017.12 - EP); A61P 9/12 (2017.12 - EP); A61P 43/00 (2017.12 - EP)
Citation (search report)
See references of WO 03041725A2
Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR
DOCDB simple family (publication)
WO 03041725 A2 20030522; WO 03041725 A3 20040318; AU 2002337186 A1 20030526; DE 10156249 A1 20030528; EP 1448210 A2 20040825; JP 2005511619 A 20050428; US 2004266736 A1 20041230
DOCDB simple family (application)
EP 0212550 W 20021111; AU 2002337186 A 20021111; DE 10156249 A 20011115; EP 02772410 A 20021111; JP 2003543612 A 20021111; US 49563804 A 20040513